drugset / Trial / NCT00210340
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped (Enrollment): “lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | — | Intrathecal |